Endometrium Kanserinde Bispesifik Antikorlar: Moleküler Rasyonel, Klinik Kanıtlar ve Gelecek Perspektifleri
Özet
Endometrium kanserinde moleküler sınıflandırmanın tedavi kararlarına yerleşmesi ve immün kontrol noktası inhibitörlerinin ileri hastalıkta standart tedavinin parçası hâline gelmesi, direnç mekanizmalarını eş zamanlı hedefleyebilen platformlara ilgiyi artırmıştır. Bispesifik antikorlar tümör antijeni×CD3 ile T hücrelerini yönlendirebilir, tümör antijeni×CD28 ile kostimülasyon sağlayabilir, iki immün kontrol noktasını veya immünite ile anjiyogenezi birlikte hedefleyebilir ya da aynı reseptörün iki farklı epitopuna bağlanabilir. Bu anlatı derlemesinde PubMed/MEDLINE, ClinicalTrials.gov, ASCO Meeting Library ve seçilmiş ESMO/SGO kaynakları 15 Eylül 2026'ya kadar taranarak hakemli yayınlar, kongre özetleri, kayıtlı çalışmalar ve preklinik kanıtlar ayrı düzeylerde sentezlenmiştir. Endometrium kanserinde bispesifik antikorlara ilişkin en kapsamlı güncel hakemli klinik veriler PD-1×CTLA-4 antikoru cadonilimab temelli çalışmalardan gelmektedir. CLEAR-EC çalışmasında cadonilimab-lenvatinib ile objektif yanıt oranı %40,6 ve medyan progresyonsuz sağkalım 13,8 ay; birinci basamak cadonilimab-kemoterapi ara analizinde objektif yanıt oranı %74,1 bulunmuştur. PD-1×VEGF antikoru SSGJ-707 ile kemoterapinin ASCO 2026 özetinde değerlendirilebilir hastalarda doğrulanmış yanıt oranları iki doz kohortunda %85,7 ve %80,0 iken, derece ≥3 tedavi ilişkili advers olay oranı %68,8'dir; bu veri henüz yalnızca kongre özeti düzeyindedir. PF-07260437'de objektif klinik yanıt gözlenmemesi ve programın sonlandırılması preklinik-klinik translasyon açığının; zanidatamab ise HER2 heterojenliği ve zaman içinde hedef ekspresyonundaki değişimin öğretici bir örneğidir. CTIM-76, ivonescimab ve REGN5668/ubamatamab programlarında endometrium kanserine özgü etkinlik henüz gösterilmemiştir. Mevcut kanıtlar, bispesifik antikorları endometrium kanserinde umut verici ancak güncel standartlara karşı randomize üstünlük kanıtı henüz bulunmayan bir terapötik platform olarak konumlandırmaktadır.
Referanslar
Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229–263. doi: 10.3322/caac.21834.
Cancer Genome Atlas Research Network. Integrated genomic characterization of endometrial carcinoma. Nature. 2013;497(7447):67–73. doi: 10.1038/nature12113.
Concin N, Matias-Guiu X, Cibula D, et al. ESGO-ESTRO-ESP guidelines for the management of patients with endometrial carcinoma: update 2025. Lancet Oncol. 2025;26(8):e423–e435. doi: 10.1016/S1470-2045(25)00167-6.
Urban R, Castellano T, Doll K, et al. Endometrial cancer: a Society of Gynecologic Oncology evidence-based review and recommendations: part I. Gynecol Oncol. 2026;209:15–25. doi: 10.1016/j.ygyno.2026.04.004.
Urban R, Eskander R, Westin S, et al. Endometrial cancer: a Society of Gynecologic Oncology evidence-based review and recommendations: part II. Gynecol Oncol. 2026;209:120–130. doi: 10.1016/j.ygyno.2026.05.006.
Eskander RN, Sill MW, Beffa L, et al. Pembrolizumab plus chemotherapy in advanced endometrial cancer. N Engl J Med. 2023;388(23):2159–2170. doi: 10.1056/NEJMoa2302312.
Mirza MR, Chase DM, Slomovitz BM, et al. Dostarlimab for primary advanced or recurrent endometrial cancer. N Engl J Med. 2023;388(23):2145–2158. doi: 10.1056/NEJMoa2216334.
Makker V, Colombo N, Casado Herráez A, et al. Lenvatinib plus pembrolizumab for advanced endometrial cancer. N Engl J Med. 2022;386(5):437–448. doi: 10.1056/NEJMoa2108330.
Baethge C, Goldbeck-Wood S, Mertens S. SANRA—a scale for the quality assessment of narrative review articles. Res Integr Peer Rev. 2019;4:5. doi: 10.1186/s41073-019-0064-8.
Herrera M, Pretelli G, Desai J, et al. Bispecific antibodies: advancing precision oncology. Trends Cancer. 2024;10(10):893–919. doi: 10.1016/j.trecan.2024.07.002.
O'Brien E, Mayer CM, Arend RC. Exploring T-cell bispecific antibodies in gynecologic malignancy. Gynecol Oncol Rep. 2025;59:101772. doi: 10.1016/j.gore.2025.101772.
Parola S, Colombo I. Bispecific antibodies in the treatment of epithelial ovarian, endometrial, and cervical cancer: an overview of current applications, challenges, and emerging opportunities. Explor Target Antitumor Ther. 2025;6:1002345. doi: 10.37349/etat.2025.1002345.
Shui L, Wu D, Yang K, et al. Bispecific antibodies: unleashing a new era in oncology treatment. Mol Cancer. 2025;24(1):212. doi: 10.1186/s12943-025-02390-y.
Greiner SM, Mauermann J, Lutz MS, et al. T cell-engaging CD276×CD3 bispecific antibody for treatment of endometrial cancer. J Transl Med. 2025;23(1):825. doi: 10.1186/s12967-025-06825-4.
Zhu M, Madia P, Crawford A, et al. Translational findings support regimen selection for first-in-human study of ubamatamab (MUC16×CD3 bispecific antibody) in patients with recurrent ovarian cancer. Clin Transl Sci. 2024;17(12):e70082. doi: 10.1111/cts.70082.
Zong L, Yu S, Mo S, et al. B7-H4 further stratifies patients with endometrial cancer exhibiting a nonspecific molecular profile. Arch Pathol Lab Med. 2023;147(11):1288–1297. doi: 10.5858/arpa.2022-0182-OA.
Lumish M, Chui MH, Zhou Q, et al. A phase 2 trial of zanidatamab in HER2-overexpressed advanced endometrial carcinoma and carcinosarcoma (ZW25-IST-2). Gynecol Oncol. 2024;182:75–81. doi: 10.1016/j.ygyno.2023.12.028.
Gullovsen VL, Pavlicenco D, Hjelmeland ME, et al. High expression of the ADC target Claudin-6 associates with aggressive endometrial cancer and remains high in metastatic lesions. BJC Rep. 2026;4(1):17. doi: 10.1038/s44276-026-00225-x.
Kojima M, Sugimoto K, Tanaka M, et al. Prognostic significance of aberrant Claudin-6 expression in endometrial cancer. Cancers (Basel). 2020;12(10):2748. doi: 10.3390/cancers12102748.
National Library of Medicine (US). A phase 1/2 study of REGN5668 (MUC16×CD28) administered in combination with other agents in MUC16-positive malignancies [Internet]. Bethesda (MD): ClinicalTrials.gov; 2020– [updated 2025 Nov 21; cited 2026 Sep 15]. Available from: https://clinicaltrials.gov/study/NCT04590326
Yan F, Cruz-Correa M, Specht J, et al. A phase 1 study of PF-07260437, a B7-H4×CD3 bispecific T-cell engager, in patients with advanced or metastatic breast, ovarian, and endometrial cancer. Invest New Drugs. 2026;44(4):305–316. doi: 10.1007/s10637-026-01614-2.
National Library of Medicine (US). A phase 1 first-in-human study of CTIM-76 in recurrent ovarian cancer and other advanced CLDN6-positive solid tumors [Internet]. Bethesda (MD): ClinicalTrials.gov; 2024– [cited 2026 Sep 15]. Available from: https://clinicaltrials.gov/study/NCT06515613
Context Therapeutics. Context Therapeutics announces positive interim efficacy and safety results from ongoing phase 1 clinical trial for CTIM-76 [press release on the Internet]. Philadelphia: Context Therapeutics; 2026 Jun 15 [cited 2026 Sep 15]. Available from: https://contexttherapeutics.gcs-web.com/news-releases/news-release-details/context-therapeutics-announces-positive-interim-efficacy-and
Zhou L, Zhao J, Li S, et al. Cadonilimab plus lenvatinib in advanced endometrial cancer: the multicenter single-arm phase II CLEAR-EC trial. Nat Commun. 2026 Sep 4. doi: 10.1038/s41467-026-77467-3. Epub ahead of print.
Lin J, Liu T, Chen J, et al. Efficacy and safety of cadonilimab combined with chemotherapy as the first-line treatment for primary advanced or recurrent endometrial cancer: a prospective single-arm open-label phase II clinical trial [study protocol]. BMJ Open. 2025;15:e094649. doi: 10.1136/bmjopen-2024-094649.
Liu B, Chen J, Chen L, et al. Efficacy and safety of cadonilimab combined with chemotherapy as first-line treatment for primary advanced or recurrent endometrial cancer: an interim analysis of a prospective, single-arm, open-label phase II trial. Gynecol Oncol. 2026;207 Suppl:14–22. doi: 10.1016/j.ygyno.2026.03.014.
Zhou Q, Long X, Wang D, et al. A phase 2 study evaluating SSGJ-707 (PF-08634404), a PD-1/VEGF bispecific antibody, plus chemotherapy in patients with first-line advanced/recurrent endometrial cancer [abstract]. J Clin Oncol. 2026;44(16 Suppl):5627. doi: 10.1200/JCO.2026.44.16_suppl.5627.
National Cancer Institute. Ivonescimab for the treatment of metastatic or recurrent endometrial cancer and cervical cancer [Internet]. Bethesda (MD): National Cancer Institute; 2026 [cited 2026 Sep 15]. Available from: https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2025-02841
O'Cearbhaill RE, Moroney JW, Martin LP, et al. A phase 1/2 study of REGN5668, a MUC16×CD28 costimulatory bispecific antibody, in combination with other targeted therapies, in patients with recurrent ovarian or endometrial cancer: trial in progress update [abstract]. J Clin Oncol. 2026;44(16 Suppl):TPS5639. doi: 10.1200/JCO.2026.44.16_suppl.TPS5639.
Bielski P, Barczyński J, Mikitiuk M, et al. The bispecific antibody targeting VISTA and PD-L1 shows enhanced tumor inhibitory activity in pancreatic, endometrial and breast cancers compared to mono- and combination immune checkpoint blockade. Front Immunol. 2025;16:1486799. doi: 10.3389/fimmu.2025.1486799.
Crombie JL, Graff T, Falchi L, et al. Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapy. Blood. 2024;143(16):1565–1575. doi: 10.1182/blood.2023022432.
Eskander RN, Sill MW, Beffa L, et al. Updated overall survival analysis and examination of subsequent therapy in endometrial cancer patients treated with pembrolizumab plus carboplatin/paclitaxel as compared with carboplatin/paclitaxel plus placebo in the NRG-GY018 trial [abstract]. J Clin Oncol. 2026;44(16 Suppl):5502. doi: 10.1200/JCO.2026.44.16_suppl.5502.
Powell MA, Roed H, Willmott LJ, et al. Four-year survival outcomes with dostarlimab plus chemotherapy in mismatch repair deficient/microsatellite instability-high primary advanced or recurrent endometrial cancer in the RUBY trial. Gynecol Oncol. 2026. doi: 10.1016/j.ygyno.2026.05.008. Epub ahead of print.
Makker V, Colombo N, Casado Herráez A, et al. Lenvatinib plus pembrolizumab in previously treated advanced endometrial cancer: updated efficacy and safety from the randomized phase III Study 309/KEYNOTE-775. J Clin Oncol. 2023;41(16):2904–2910. doi: 10.1200/JCO.22.02152.
Pang X, Huang Z, Zhong T, et al. Cadonilimab, a tetravalent PD-1/CTLA-4 bispecific antibody with trans-binding and enhanced target binding avidity. MAbs. 2023;15(1):2180794. doi: 10.1080/19420862.2023.2180794.